By studying the literature about tetracyclines (TCs), it becomes clearly evident that TCs are very dynamic molecules. In some cases, their structure-activity-relationship (SAR) are well known, especially against bacteria, while against other targets, they are virtually unknown. In other diverse fields of research—such as neurology, oncology and virology—the utility and activity of the tetracyclines are being discovered and are also emerging as new technological fronts. The first aim of this paper is to classify the compounds already used in therapy and prepare the schematic structure that includes the next generation of TCs. The second aim of this work is to introduce a new framework for the classification of old and new TCs, using a medicinal chemistry approach to the structure of those drugs. A fully documented Structure-Activity-Relationship (SAR) is presented with the analysis data of antibacterial and nonantibacterial (antifungal, antiviral and anticancer) tetracyclines. The lipophilicity and the conformational interchangeability of the functional groups are employed to develop the rules for TC biological activity.
References
[1]
Wainwright, M. Miracle Cure: The Story of Antibiotics; Blackwell: Oxford, UK, 1990.
[2]
Connell, S.; Tracz, R.; Nierhaus, D.; Taylor, K.H.; Diane, E. Ribosomal Protection Proteins and Their Mechanism of Tetracycline Resistance. Antimicrob. Agents Chemother. 2003, 47, 3675–3681, doi:10.1128/AAC.47.12.3675-3681.2003.
[3]
Broderson, D.E.; Clemenson, W.M.; Carter, A.P.; Morgan-Warren, R.J.; Wimberly, B.T.; Ramakrishan, V. The structural basis for the action of the antibiotics tetracycline. Cell 2000, 103, 1143–1154, doi:10.1016/S0092-8674(00)00216-6.
[4]
Nelson, M.L.; Ismail, M.Y. The Antibiotic and Nonantibiotic Tetracyclines. Comp. Med. Chem. 2007, 7, 742–775.
[5]
Nelson, M.L. Chemical and Biological Dynamics of Tetracyclines. Adv. Dent. Res. 1998, 12, 5–11, doi:10.1177/08959374980120011901.
[6]
Carlotti, B.; Fuoco, D.; Elisei, F. Fast and ultrafast spectroscopic investigation of tetracycline derivatives in organic and aqueous media. Phys. Chem. Chem. Phys. 2010, 12, 15580–15591, doi:10.1039/c0cp00044b. 20661497
[7]
Chopra, I.; Roberts, M. Tetracycline antibiotics: Mode of action, application, molecular biology and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001, 65, 232–260, doi:10.1128/MMBR.65.2.232-260.2001. 11381101
[8]
D’Agostino, P.; Ferlazzo, V.; Milano, S.; La Rosa, M.; Di Bella, G. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int. Immunopharmacol. 2001, 1, 1765–1776, doi:10.1016/S1567-5769(01)00100-X.
[9]
Thong, Y.H.; Ferrante, A. Inhibition of mitogen-induced human lymphocyte proliferative responses to tetracycline analogues. Clin. Exp. Immunol. 1979, 35, 443–446. 455782
[10]
Martin, R.R.; Warr, G.A.; Couch, R.B.; Yeager, H.; Knight, V. Effects of tetracyclines on leukotaxis. J. Infect. Dis. 1974, 129, 110–116, doi:10.1093/infdis/129.2.110.
[11]
Pruzanski, W.; Laliberte, F.; Stefanski, E.; Vadas, P. Inhibition of enzymatic activity of phospholipase A2 by minocycline and doxycycline. Biochem. Pharmacol. 1992, 44, 1165–1170, doi:10.1016/0006-2952(92)90381-R.
[12]
Amin, A.R.; Patel, R.N.; Thakker, G.D.; Lowenstein, C.J. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett. 1997, 410, 259–264, doi:10.1016/S0014-5793(97)00605-4.
[13]
Cosentino, U.; Varí, M.R.; Saracino, A.A.G.; Pitea, D.; Moro, G.; Salmona, M. Tetracycline and its analogues as inhibitors of amyloid fibrils: Searching for a geometrical pharmacophore by theoretical investigation of their conformational behavior in aqueous solution. J. Mol. Model. 2005, 11, 17–25, doi:10.1007/s00894-004-0213-x.
[14]
Chen, M.; Ona, V.O.; Li, M.; Ferrante, R.J.; Fink, K.B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L.A.; Hersch, S.M.; et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6, 797–801, doi:10.1038/77528. 10888929
[15]
Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Chan, P.; Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA 1999, 96, 13495–13500.
[16]
Thomas, M.; Le, W.D.; Jankovic, J. Minocycline and Other Tetracycline Derivatives: A Neuroprotective Strategy in Parkinson’s Disease and Huntington’s Disease. Clin. Neuropharmacol. 2003, 26, 18–23, doi:10.1097/00002826-200301000-00005.
[17]
Stetler-Steveson, W.G. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993, 7, 1434–1441. 8262328
[18]
Duivenvoorden, W.C.; Hirte, H.W.; Singh, G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invas. Metast. 1997, 17, 312–322.
[19]
Rubins, J.B.; Charboneau, D.; Alter, M.D.; Bitterman Kratzke, R.A. Inhibition of mesothelioma cell growth in vitro by doxycycline. J. Lab. Clin. Med. 2001, 138, 101–106, doi:10.1067/mlc.2001.116591.
[20]
Ermak, G.; Cancasci, V.J.; Davies, K.J.A. Cytotoxic effect of doxycycline and its implications for tet-on gene expression systems. Anal. Biochem. 2003, 318, 152–154, doi:10.1016/S0003-2697(03)00166-0.
[21]
Lambs, L.; Reverend, B.D.; Kozlowski, H.; Berthon, G. Metal-ion tetracycline interactions in biological fluids. 9. Circular dichroism spectra of calcium and magnesium complexes with tetracycline, oxytetracycline, doxycycline and chlortetracycline and a discussion of their binding modes. Inorg. Chem. 1988, 41, 638–641.
[22]
Charest, M.G.; Lerner, C.D.; Brubaker, J.D.; Siegel, D.R.; Myers, A.G. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005, 308, 395–398, doi:10.1126/science.1109755.
[23]
Nelson, M.L.; Levy, S. The history of the tetracyclines. Ann. NY Acad. Sci. Antimicrob. Ther. Rev. 1241, 17–32.
[24]
Howlett, D.; George, A.; Owen, D.; Ward, R.; Mqarkekwell, R. Common structural determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitor of Alzheimer B-amyloid fibril formation. Biochem. J. 1999, 343, 419–423, doi:10.1042/0264-6021:3430419.
[25]
Cosentino, U.; Pitea, D.; Moro, G.; Saracino, A.; Caria, P.; Vari, R.; Colombo, L.; Forloni, G.; Tagliavini, F.; Salmona, M. The anti-fibrillogenic activity of tetracyclines on PrP 106-126: A 3D-QSAR study. J. Mol. Model. 2008, 14, 987–994, doi:10.1007/s00894-008-0348-2.
[26]
De Luigi, A.; Colombo, L.; Diomede, L.; Capobianco, R.; Mangieri, M. The Efficacy of Tetracycline in Peripheral and intracerebral Prion Infection. PLoS One 2008, 3, e1888, doi:10.1371/journal.pone.0001888. 18365024
[27]
Weng, Y.C.; Kriz, J. Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp. Neurol. 2007, 204, 433–442, doi:10.1016/j.expneurol.2006.12.003.
[28]
Khan, M.; Musarrat, J. Interactions of tetracycline and its derivatives with DNA in vitro in presence of metal ions. Int. J. Biol. Macromol. 2003, 33, 49–56, doi:10.1016/S0141-8130(03)00066-7.
[29]
Tang, X.N.; Wang, O.; Koike, M.A.; Chang, D.; Goris, M.L.; Blankenbag, F.G. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J. Nucl. Med. 2007, 11, 1822–1828.
[30]
Lemaitre, M.; Guetard, D.; Henin, Y.; Montagnier, L.; Zerial, A. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res. Virol. 1990, 141, 5–16, doi:10.1016/0923-2516(90)90052-K.
[31]
Zink, M.C.; Uhrlaub, J.; DeWitt, J.; Voelker, T.; Bullock, B.; Mankowski, J. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005, 293, 2003–2011, doi:10.1001/jama.293.16.2003.
[32]
Michaelis, M.; Kleinschmidt, M.C.; Doerr, H.W.; Cinatl, J. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J. Antimicrob. Chemother. 2007, 60, 981–986, doi:10.1093/jac/dkm307.
[33]
Dutta, K.; Basu, A. Use of minocycline in viral infections. Indian J. Med. Res. 2011, 133, 467–470. 21623029
[34]
Grossen, M.; Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 1992, 89, 5547–5551, doi:10.1073/pnas.89.12.5547.
[35]
Halterman, M.W. An improved method for the study of apoptosis-related genes using the tet-on system. J. Biomol. Screen. 2011, 16, 332–337, doi:10.1177/1087057110397355.
[36]
Available online: http://www.freshpatents.com/ (accessed on 19 May 2012). and Google Patents Search Engine.
[37]
Myers, Andrew G. Department of Chemistry, Harvard University: Boston, USA. Available online: http://www.chem.harvard.edu/groups/myers/index.html/ (accessed on 19 May 2012).
[38]
Xiao, X.-Y.; Hunt, D.K.; Zhou, J.; Clark, R.B.; Dunwoody, N.; Fyfe, C.; Grossman, T.H.; O’Brien, W.J.; Plamondon, L.; R？nn, M.; et al. Fluorocyclines. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycl: A Potent, Broad Spectrum Antibacterial Agent. J. Med. Chem. 2012, 55, 597–605, doi:10.1021/jm201465w.
[39]
Golub, L.M.; Lee, H.M.; McNamara, T.F. Minocycline Reduce Gingival Collagenolytic Activity during Diabetes: Preliminary Observations and a Proposed New Mechanism of Action. J. Periodontal Res. 1983, 18, 516–526, doi:10.1111/j.1600-0765.1983.tb00388.x.
[40]
McNamara, T.F.; Golub, L.M.; D’Angelo, G. The Synthesis and Characterization of a Non-antibacterial Chemically Modified Tetracycline. J. Dent. Res. 1986, 65, 266.
[41]
Doershuk, A.P.; Bitler, B.A.; McCormick, J.R.D. Reversible isomerization in the tetracycline family. J. Am. Chem. Soc. 1955, 77, 467.
[42]
Silvia, P.P.; Guerra, W.; Silveira, J.N.; Ferreira, A.M.C.; Bortolotto, T.; Fischer, F.L.; Terenzi, H.; Neves, A.; Pereira-Maia, E.C. Two new ternary complexes of copper (II) with tetracycline or doxycycline and 1,10-Phenantroline and their potential as antitumoral: Cytotoxicity and DNA cleavage. Inorg. Chem. 2011, 50, 6414–6424, doi:10.1021/ic101791r. 21692452
[43]
Bortolotto, T.; Silva, P.P.; Neves, A.; Pereira-Maia, E.C.; Terenzi, H. Photoinduced DNA Cleavage promoted by two Copper (II) complexes of tetracyclines and 1,10-Phenanthroline. Inorg. Chem. 2011, 50, 10519–10521, doi:10.1021/ic201349s. 21970295
[44]
Duarte, H.A.; Carvalho, S.; Paniago, E.B.; Simas, A.M. Importance of tautomers in the chemical behavior of tetracyclines. J. Pharm. Sci. 1999, 88, 111–120, doi:10.1021/js980181r.
